Article
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Breast cancer research and treatment - 1 Jun 2012
Ferraldeschi Roberta, Arnedos Monica, Hadfield Kristen D, A'Hern Roger, Drury Suzie, Wardley Andrew, Howell Anthony, Evans D Gareth, Roberts Stephen A, Smith Ian, Newman William G, Dowsett Mitch
Abstract excerpt
Single nucleotide polymorphisms (SNPs) in the gene encoding aromatase (CYP19A1) have been associated with differential benefit from letrozole treatment in metastatic breast cancer (mBC) patients, but validation is lacking. The aim was to investigate whether polymorphic variation of CYP19A1 and enzymes involved in estrogen and aromatase inhibitors (AIs) metabolism are associated with efficacy of AIs. 308 Women...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
